+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incretin physiology and its role in type 2 diabetes mellitus



Incretin physiology and its role in type 2 diabetes mellitus



Journal of the American Osteopathic Association 110(7 Suppl 7): Es20-Es24



Incretins are hormones that are released after ingestion of a meal and augment the secretion of insulin. Current research suggests that GLP-1 (glucagon-like peptide 1) is the most important. Their action is terminated by enzymes known as dipeptidyl peptidase-4 (DPP-4). The observation that the incretin response may be diminished in individuals with type 2 diabetes mellitus has led to advances in the management of this disease. Agents that act as incretin mimetics, such as exenatide and liraglutide, and DPP-4 inhibitors, such as sitagliptin phosphate and saxagliptin, improve glycated hemoglobin levels either as monotherapy or in combination with other agents. Importantly, these agents either lead to weight loss or are weight neutral and are associated with a low risk of hypoglycemia--properties that further contribute to their clinical utility.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053810381

Download citation: RISBibTeXText

PMID: 20644202


Related references

The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology 297(1-2): 127-136, 2008

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic Journal of Medicine 76 Suppl 5: S12-S19, 2010

On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Danish Medical Bulletin 51(4): 364-370, 2005

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. Canadian Journal of Diabetes 35(5): 518-527, 2011

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs & Aging 25(11): 913-925, 2008

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 33(5): 511-527, 2011

Incretin therapy for type 2 diabetes mellitus. Advances in Therapy 27(12): 881-894, 2011

The role of incretin on diabetes mellitus. Acta Medica Indonesiana 41(4): 205-212, 2010

The incretin system in the management of type 2 diabetes mellitus. Clinical Medicine 10(5): 491-495, 2011

Targeting the incretin system in type 2 diabetes mellitus. Mount Sinai Journal of Medicine, New York 76(3): 244-256, 2009

Incretin-based therapies in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 93(10): 3703-3716, 2008

Treatment of type 2 diabetes mellitus and the incretin system. South Dakota Medicine 60(5): 197, 199-197, 199, 2007

Incretin-based therapy of type 2 diabetes mellitus. Current Protein & Peptide Science 10(1): 46-55, 2009

Incretin based therapies for type 2 diabetes mellitus. Journal of the Indian Medical Association 106(6): 373-4, 383, 388, 2008